STOCK TITAN

Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

ADAR1 Capital Management, LLC and its manager Daniel Schneeberger report beneficial ownership of Editas Medicine, Inc. common stock. Private investment funds managed by ADAR1 Capital Management hold 8,889,000 shares of Editas common stock, representing 5.8% of the class based on 153,530,898 shares outstanding as of June 30, 2026.

Both ADAR1 Capital Management and Mr. Schneeberger report shared voting and dispositive power over the 8,889,000 shares and no sole voting or dispositive power. Mr. Schneeberger files as a control person of ADAR1 Capital Management, which is characterized as an investment adviser. The filing is made jointly under a joint filing agreement.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 8,889,000 shares Common stock of Editas Medicine held by funds managed by ADAR1 Capital Management
Percent of class 5.8% Portion of Editas Medicine common stock beneficially owned by the reporting persons
Shares outstanding 153,530,898 shares Editas Medicine common shares outstanding as of June 30, 2026
Shared voting power 8,889,000 shares Shares over which ADAR1 Capital Management and Daniel Schneeberger have shared voting power
Shared dispositive power 8,889,000 shares Shares over which ADAR1 Capital Management and Daniel Schneeberger have shared dispositive power
beneficially owned financial
"Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 8,889,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 8,889,000.00"
control person financial
"Mr. Schneeberger is filing this as a control person in respect of shares beneficially owned"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
investment adviser financial
"ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E)."
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

What stake in Editas Medicine (EDIT) does ADAR1 Capital Management report?

ADAR1 Capital Management reports beneficial ownership of 8,889,000 shares of Editas Medicine common stock, representing 5.8% of the outstanding shares, held by private investment funds it manages.

How was the 5.8% ownership in Editas Medicine (EDIT) calculated?

The 5.8% ownership is based on 153,530,898 Editas Medicine common shares outstanding as of June 30, 2026, as disclosed in Editas Medicine’s Form 10-Q for the quarter ended June 30, 2026.

Who are the reporting persons in this Schedule 13G for Editas Medicine (EDIT)?

The reporting persons are ADAR1 Capital Management, LLC, a Texas limited liability company, and Daniel Schneeberger, a citizen of Switzerland and the sole manager of ADAR1 Capital Management.

What voting and dispositive powers over Editas (EDIT) shares does ADAR1 report?

ADAR1 Capital Management and Daniel Schneeberger each report 0 sole voting and dispositive power and 8,889,000 shares of shared voting and shared dispositive power over Editas common stock.

In what capacity does Daniel Schneeberger report Editas (EDIT) ownership?

Daniel Schneeberger reports the Editas stake as a control person with indirect beneficial ownership of shares held by funds managed by ADAR1 Capital Management, where he serves as the sole manager.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





28106W103

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 8,889,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Editas Medicine, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 153,530,898 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 8,889,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Editas Medicine, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 153,530,898 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 5, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:08/14/2026
Exhibit Information

Exhibit A: Joint Filing Agreement